The financial world is abuzz with the latest news surrounding CME Group (NASDAQ:CME). According to Bloomberg.com, thirteen research firms have been covering the company, and their average rating for CME Group Inc. is “Hold.” This rating comes after one investment analyst rated the stock as a sell recommendation while four gave it a hold recommendation. Five of them also issued a buy recommendation on the company, making it an intriguing option for potential investors.
But what can we expect from CME Group in the next 12 months? Brokerages that recently updated their coverage on the stock predict an average 12-month price objective of $215.64. While this may mean that we should not expect an immediate spike in its value, there is still reason to believe that it could be a promising long-term investment.
One major factor in CME Group’s expected growth is its most recent earnings report released on April 26th of this year. The company came out ahead of the consensus estimate with earnings per share (EPS) coming in at $2.42 compared to predictions of $2.36 per share. Additionally, its revenue totaled $1.44 billion during this quarter, outperforming initial expectations by $20 million.
It’s worth noting that CME Group operates a derivatives marketplace, offering extensive futures and options products for risk management across all major asset classes such as interest rates, equity indexes, FX markets,and commodities. Its marketplaces make for a significant part of its operations’ diverse portfolio.
The results from CME Group’s quarterly performance are even more impressive when viewed against its benchmark figures in previous years.In comparison to Q1 of 2022,it managed to increase quarterly revenue by 7.1 percent.While maintaining an impressive return on equity(10.,88%) coupled with net margin(55 .99%).
Given consistent performances like these and generally positive reviews among industry insiders,CME is expected to post a more substantial annualized profit.This would likely appeal to potential investors interested in long-term growth opportunities.
In conclusion, while CME Group has been given a “Hold” rating by most research firms at present- it’s an encouraging sign for anyone who appreciates long-term investments: the company’s fiscal resilience and position as one of the top players in their field could yield significant dividends over time.
[bs_slider_forecast=”CME”]
CME Group: Analyst Ratings, Investment Activity, and Financial Indicators
CME Group, Inc. has been on the radar of various analysts in recent months. Rosenblatt Securities reiterated a “sell” rating and set a target price of $161.00 in a research note released on April 5th, while Morgan Stanley lifted their target price for the company from $201.00 to $208.00 and gave it an “equal weight” rating in a report on April 11th.
Meanwhile, JPMorgan Chase & Co. lowered their target price from $196.00 to $194.00 and gave CME Group a “neutral” rating on April 19th. StockNews.com recently began covering the company with a “hold” rating on May 18th.
Oppenheimer provided bullish commentary by lifting their price target for CME Group from $213.00 to $221.00 and giving the stock an “outperform” rating in a report issued on April 12th.
CME Group opened at $180.07 on May 25th with a fifty-day moving average of $186.69 and a two-hundred day moving average of $180.55, placing its market cap at $64.77 billion.
The company operates as a derivatives marketplace offering futures and options products for risk management across all major asset classes based on interest rates, equity indexes, FX, energy, agriculture commodities, and metals.
On June 27th, CME Group disclosed its latest quarterly dividend payment – shareholders of record on June 9th will receive a dividend payout of $1.10 per share – reflecting an annualized dividend yieldof2 .44%.
Recent investment activity suggests increased interest from hedge funds and other institutional investors towards CME Group’s stock holdings in recent quarters: Envestnet Asset Management Inc., Greenleaf Trust, Balentine LLC., Aigen Investment Management LP,andXponanceInc.are among those who have recently acquired or increased their holdings in CME Group, with an 85.09% ownership of the stock by institutional investors and hedge funds.
CME Group’s financial indicators show a price-to-earnings ratio (P/E) of 22.88, price-to-earnings-growth ratio (PEG) of 4.46, debt-to-equity ratio(D/E)of0 .13, beta of0 .41,and52-weekhigh/low rangeof$212.09/$166.54.
